This news or article is intended for readers with certain scientific or professional knowledge in the field. A new multi-institution, dose-determining clinical trial of a compound against metastatic, castration-resistant prostate cancer showed promising results, researchers reported in Clinical Cancer Research. The phase 1b/2a study of the pan-BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide was...
Tag: <span>Enzalutamide</span>
Post
New Clues in Resistance to Mainstay Drug for Patients with Metastatic Prostate Cancer
This news or article is intended for readers with certain scientific or professional knowledge in the field. Enzalutamide is one of the main treatments for patients with metastatic, castration-resistant prostate cancer — the lethal form of the disease. However, treatment options are limited for those who develop resistance to enzalutamide. Now, a multi-institution team has...
Post
Bald men at higher risk of severe case of Covid-19, research finds
Researchers suggested that baldness should be considered a risk factor, dubbing it the ‘Gabrin sign’ By Jennifer Rigby 4 June 2020 • 8:33pm Bald men may be at higher risk of suffering from severe Covid-19 symptoms, emerging evidence suggests. The link is so strong that some researchers are suggesting baldness should be considered a risk...
Post
Reusable Textiles to Repel Viruses
Prostate cancer therapies have shown significant advances during the past decade, with multiple new therapies being introduced for patients with advanced disease. Now, the early results of a clinical trial published in the New England Journal of Medicine (NEJM) reveals for the first time that therapies based on tumor genetics – specifically DNA repair defects...
Post
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
DANA-FARBER CANCER INSTITUTE After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute’s Lank Center for...